Drug1st-line biologic line
Benralizumab
Anti–IL-5Rα monoclonal antibody (ADCC-mediated eosinophil depletion)
- Response rate
- Near-complete eosinophil depletion
- Onset
- 4 weeks
- Route
- SC 30mg every 4–8 weeks
- Line
- 1st-line biologic
- IgM effect
- Reduces polyp score
- Evidence level
- green
- Trial phase
- Phase 4
Evidence summary
Binds IL-5Rα and induces antibody-dependent cellular cytotoxicity (ADCC), depleting eosinophils and basophils. OSTRO trial showed significant NPS and congestion improvement. FDA-approved 2024 for CRSwNP. Unique mechanism achieving near-complete tissue eosinophil depletion.
Approved indications
Conditions for which Benralizumab has regulatory approval (not specific to rare diseases covered here):
Severe Eosinophilic AsthmaChronic Rhinosinusitis with Nasal Polyps
Drug identifiers
| DrugBank | DB11600 ↗ |
| ATC Code | R03DX10 |
| Open Targets | CHEMBL3137343 ↗ |
Molecular targets
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-5 | Eosinophil survival factor | Elevated | established |
| Eosinophils | Effector granulocytes | Massively infiltrated in tissue | established |